Cho E, Caldwell J, Pandey K, et al. CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Di Caro V, Cho E, Knezovich N, et al. Top-Line CSF Biomarker Outcomes From The Phase 2 Clinical Trial SHINE In Alzheimer’s Patients. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Di Caro V, Pandey K, Cho E, et al. Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain. e-Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Lizama B, Duong D, Pandey K, et al. Plasma Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.
Di Caro V, Pandey K, Lizama B, et al. Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer’s Patients. Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Lizama B, Cho E, Duong D, et al. Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer’s Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented Oct 2023 at: Clinical Trials on Alzheimer’s Disease (CTAD); Boston, Massachusetts.
Pandey K, Waybright L, Duong DM, et al. CSF Proteomics Biomarker Analysis from the SPARC Clinical Trial: to Assess the Effect of the Sigma-2 Receptor (S2R) Modulator CT1812 in Alzheimer’s Disease Patients. Oral presentation at: 2022 Alzheimer’s Association’s International Conference (AAIC); San Diego, CA.
Seyfried N, Waybright L, Duong D, et al. Proteomic Analysis of CSF in a Phase 2 Clinical Trial for AD to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases; Barcelona, Spain.
Cognition publishes evidence that treatment with CT1812 improves disease-related biology in patients with Alzheimer’s disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Pittsburgh, August 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease. The study is
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812 Read More »
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
